Epi proLung® – Liquid biopsy test for lung cancer detection
Diagnosing lung cancer remains challenging and represents a highly unmet medical need. Radiological screening methods suffer from a high false positivity rate and therefore complementary confirmatory diagnostic methods are urgently needed. A reflex test that clarifies indeterminate findings will aid in earlier identification of illness, improved outcomes, and lower costs of treatment by reducing unnecessary procedures.
Our new assay Epi proLung® (in clinical development) is based on a combination of proprietary Epigenomics DNA methylation biomarkers SHOX2 and PTGER4. In a first clinical evaluation study, the DNA methylation panel displayed high sensitivity in detecting lung cancer.
The development is partly financed by a grant of up to EUR 2.8 million from the European Commission within the framework of the Horizon 2020 program.
The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 672680.